(TMV) TeamViewer - Ratings and Ratios
Remote Access, Enterprise Connectivity, Frontline Workflow, Device Support, AR
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 42.6% |
| Value at Risk 5%th | 55.6% |
| Relative Tail Risk | -20.73% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.96 |
| Alpha | -45.51 |
| CAGR/Max DD | -0.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.515 |
| Beta | 0.196 |
| Beta Downside | 0.009 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.99% |
| Mean DD | 27.81% |
| Median DD | 28.39% |
Description: TMV TeamViewer November 13, 2025
TeamViewer SE (XETRA: TMV) develops and sells remote-connectivity software, including the flagship TeamViewer Remote for consumer and SMB users, the enterprise-grade Tensor platform, Frontline for digital workflow assistance, and Dex for AI-driven diagnostics. The suite is complemented by AR/MR tools that target logistics, manufacturing, and after-sales processes. Founded in 2005 and based in Göppingen, Germany, the firm operates globally through a subscription-based SaaS model.
Key recent metrics (FY 2023): revenue of €735 million (+13 % YoY), annual recurring revenue (ARR) growth of ~15 % driven largely by enterprise contracts, and a net-loss of €45 million reflecting continued investment in product expansion and R&D. The remote-work trend and increasing digitalization of field services act as sector tailwinds, while pricing pressure from competitors such as LogMeIn and emerging AI-enabled platforms represents a material risk. The company’s gross margin remains robust at ~80 %, but operating leverage is constrained by high sales-and-marketing spend (≈30 % of revenue).
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed financial model and scenario analysis for TMV.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (115.6m TTM) > 0 and > 6% of Revenue (6% = 43.9m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -8.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -105.3% (prev -67.85%; Δ -37.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 217.1m > Net Income 115.6m (YES >=105%, WARN >=100%) |
| Net Debt (969.6m) to EBITDA (254.8m) ratio: 3.81 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (158.0m) change vs 12m ago -0.26% (target <= -2.0% for YES) |
| Gross Margin 87.38% (prev 87.07%; Δ 0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.34% (prev 64.32%; Δ -9.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.11 (EBITDA TTM 254.8m / Interest Expense TTM 33.6m) >= 6 (WARN >= 3) |
Altman Z'' -1.63
| (A) -0.46 = (Total Current Assets 107.2m - Total Current Liabilities 876.4m) / Total Assets 1.67b |
| (B) 0.07 = Retained Earnings (Balance) 108.8m / Total Assets 1.67b |
| (C) 0.15 = EBIT TTM 205.5m / Avg Total Assets 1.34b |
| (D) 0.15 = Book Value of Equity 227.9m / Total Liabilities 1.54b |
| Total Rating: -1.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.10
| 1. Piotroski 5.0pt |
| 2. FCF Yield 11.24% |
| 3. FCF Margin 28.84% |
| 4. Debt/Equity 7.60 |
| 5. Debt/Ebitda 3.81 |
| 6. ROIC - WACC (= 31.10)% |
| 7. RoE 108.1% |
| 8. Rev. Trend 99.11% |
| 9. EPS Trend 48.61% |
What is the price of TMV shares?
Over the past week, the price has changed by +2.08%, over one month by +4.16%, over three months by -32.36% and over the past year by -38.71%.
Is TMV a buy, sell or hold?
What are the forecasts/targets for the TMV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.5 | 77.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.7 | -19.7% |
TMV Fundamental Data Overview December 21, 2025
Market Cap EUR = 904.9m (904.9m EUR * 1.0 EUR.EUR)
P/E Trailing = 7.8973
P/E Forward = 4.7304
P/S = 1.2382
P/B = 6.7372
P/EG = 0.3033
Beta = 1.05
Revenue TTM = 730.8m EUR
EBIT TTM = 205.5m EUR
EBITDA TTM = 254.8m EUR
Long Term Debt = 537.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 460.1m EUR (from shortTermDebt, last quarter)
Debt = 997.5m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 969.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.87b EUR (904.9m + Debt 997.5m - CCE 27.9m)
Interest Coverage Ratio = 6.11 (Ebit TTM 205.5m / Interest Expense TTM 33.6m)
FCF Yield = 11.24% (FCF TTM 210.8m / Enterprise Value 1.87b)
FCF Margin = 28.84% (FCF TTM 210.8m / Revenue TTM 730.8m)
Net Margin = 15.82% (Net Income TTM 115.6m / Revenue TTM 730.8m)
Gross Margin = 87.38% ((Revenue TTM 730.8m - Cost of Revenue TTM 92.2m) / Revenue TTM)
Gross Margin QoQ = 86.75% (prev 86.70%)
Tobins Q-Ratio = 1.12 (Enterprise Value 1.87b / Total Assets 1.67b)
Interest Expense / Debt = 1.04% (Interest Expense 10.4m / Debt 997.5m)
Taxrate = 26.94% (10.6m / 39.2m)
NOPAT = 150.2m (EBIT 205.5m * (1 - 26.94%))
Current Ratio = 0.12 (Total Current Assets 107.2m / Total Current Liabilities 876.4m)
Debt / Equity = 7.60 (Debt 997.5m / totalStockholderEquity, last quarter 131.2m)
Debt / EBITDA = 3.81 (Net Debt 969.6m / EBITDA 254.8m)
Debt / FCF = 4.60 (Net Debt 969.6m / FCF TTM 210.8m)
Total Stockholder Equity = 106.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.93% (Net Income 115.6m / Total Assets 1.67b)
RoE = 108.1% (Net Income TTM 115.6m / Total Stockholder Equity 106.9m)
RoCE = 31.90% (EBIT 205.5m / Capital Employed (Equity 106.9m + L.T.Debt 537.4m))
RoIC = 34.71% (NOPAT 150.2m / Invested Capital 432.6m)
WACC = 3.61% (E(904.9m)/V(1.90b) * Re(6.74%) + D(997.5m)/V(1.90b) * Rd(1.04%) * (1-Tc(0.27)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.34%
[DCF Debug] Terminal Value 79.09% ; FCFE base≈211.4m ; Y1≈223.7m ; Y5≈265.5m
Fair Price DCF = 29.62 (DCF Value 4.65b / Shares Outstanding 157.0m; 5y FCF grow 6.35% → 3.0% )
EPS Correlation: 48.61 | EPS CAGR: 6.93% | SUE: -1.71 | # QB: 0
Revenue Correlation: 99.11 | Revenue CAGR: 10.06% | SUE: -0.88 | # QB: 0
EPS next Year (2026-12-31): EPS=1.09 | Chg30d=-0.021 | Revisions Net=-3 | Growth EPS=+1.1% | Growth Revenue=+3.4%